Cunha, L.S.D.;                     Farias, I.M.;                     Nogueira, B.M.D.;                     Machado, C.B.;                     Pessoa, F.M.C.D.P.;                     Oliveira, D.D.S.;                     de Morais, G.P.;                     Thé, A.P.;                     Thé, P.M.P.;                     Moraes Filho, M.O.D.;     
    et al.    Epigallocatechin Gallate as a Targeted Therapeutic Strategy Against the JAK2V617F Mutation: New Perspectives for the Treatment of Myeloproliferative Neoplasms and Acute Myeloid Leukemia. Int. J. Transl. Med. 2025, 5, 43.
    https://doi.org/10.3390/ijtm5030043
    AMA Style
    
                                Cunha LSD,                                 Farias IM,                                 Nogueira BMD,                                 Machado CB,                                 Pessoa FMCDP,                                 Oliveira DDS,                                 de Morais GP,                                 Thé AP,                                 Thé PMP,                                 Moraes Filho MOD,         
        et al.        Epigallocatechin Gallate as a Targeted Therapeutic Strategy Against the JAK2V617F Mutation: New Perspectives for the Treatment of Myeloproliferative Neoplasms and Acute Myeloid Leukemia. International Journal of Translational Medicine. 2025; 5(3):43.
        https://doi.org/10.3390/ijtm5030043
    
    Chicago/Turabian Style
    
                                Cunha, Leidivan Sousa Da,                                 Isabelle Magalhães Farias,                                 Beatriz Maria Dias Nogueira,                                 Caio Bezerra Machado,                                 Flávia Melo Cunha De Pinho Pessoa,                                 Deivide De Sousa Oliveira,                                 Guilherme Passos de Morais,                                 André Pontes Thé,                                 PatrÃcia Maria Pontes Thé,                                 Manoel Odorico De Moraes Filho,         
         and et al.        2025. "Epigallocatechin Gallate as a Targeted Therapeutic Strategy Against the JAK2V617F Mutation: New Perspectives for the Treatment of Myeloproliferative Neoplasms and Acute Myeloid Leukemia" International Journal of Translational Medicine 5, no. 3: 43.
        https://doi.org/10.3390/ijtm5030043
    
    APA Style
    
                                Cunha, L. S. D.,                                 Farias, I. M.,                                 Nogueira, B. M. D.,                                 Machado, C. B.,                                 Pessoa, F. M. C. D. P.,                                 Oliveira, D. D. S.,                                 de Morais, G. P.,                                 Thé, A. P.,                                 Thé, P. M. P.,                                 Moraes Filho, M. O. D.,                                 Moraes, M. E. A. D.,                                 & Moreira-Nunes, C. A.        
        
        (2025). Epigallocatechin Gallate as a Targeted Therapeutic Strategy Against the JAK2V617F Mutation: New Perspectives for the Treatment of Myeloproliferative Neoplasms and Acute Myeloid Leukemia. International Journal of Translational Medicine, 5(3), 43.
        https://doi.org/10.3390/ijtm5030043